JP2021501218A5 - - Google Patents

Info

Publication number
JP2021501218A5
JP2021501218A5 JP2020544331A JP2020544331A JP2021501218A5 JP 2021501218 A5 JP2021501218 A5 JP 2021501218A5 JP 2020544331 A JP2020544331 A JP 2020544331A JP 2020544331 A JP2020544331 A JP 2020544331A JP 2021501218 A5 JP2021501218 A5 JP 2021501218A5
Authority
JP
Japan
Prior art keywords
azaspiro
nonane
isoxazole
cyclopropyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020544331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501218A (ja
JP7264905B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/058312 external-priority patent/WO2019089664A1/en
Publication of JP2021501218A publication Critical patent/JP2021501218A/ja
Publication of JP2021501218A5 publication Critical patent/JP2021501218A5/ja
Application granted granted Critical
Publication of JP7264905B2 publication Critical patent/JP7264905B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544331A 2017-11-01 2018-10-31 ファルネソイドx受容体モジュレーターとしての多環化合物 Active JP7264905B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762580064P 2017-11-01 2017-11-01
US62/580,064 2017-11-01
PCT/US2018/058312 WO2019089664A1 (en) 2017-11-01 2018-10-31 Multicyclic compounds as farnesoid x receptor modulators

Publications (3)

Publication Number Publication Date
JP2021501218A JP2021501218A (ja) 2021-01-14
JP2021501218A5 true JP2021501218A5 (https=) 2022-03-17
JP7264905B2 JP7264905B2 (ja) 2023-04-25

Family

ID=64362672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544331A Active JP7264905B2 (ja) 2017-11-01 2018-10-31 ファルネソイドx受容体モジュレーターとしての多環化合物

Country Status (7)

Country Link
US (1) US11370785B2 (https=)
EP (1) EP3704107B1 (https=)
JP (1) JP7264905B2 (https=)
KR (1) KR102731925B1 (https=)
CN (1) CN111278817B (https=)
ES (1) ES2944601T3 (https=)
WO (1) WO2019089664A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
US12492211B2 (en) * 2019-11-29 2025-12-09 Sunshine Lake Pharma Co., Ltd. Crystalline form of nitrogen-containing tricyclic compound and use thereof
AU2020390308A1 (en) * 2019-11-29 2022-06-09 Sunshine Lake Pharma Co., Ltd. Amorphous form of nitrogen-containing tricyclic compound and use thereof
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
KR20230154806A (ko) 2021-01-14 2023-11-09 엔요 파마 Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
EP4554931A1 (en) * 2022-07-12 2025-05-21 Adama Makhteshim Ltd. Process for preparing substituted benzamides
KR20260032385A (ko) * 2024-08-28 2026-03-09 주식회사유한양행 Glp-1 수용체 효능제 활성을 가진 시에노이미다졸 화합물, 이의 제조 방법, 및 이들의 의약 용도

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013101A1 (fr) 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
AU4999897A (en) 1996-10-25 1998-05-15 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
JP2006515838A (ja) 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドx受容体アゴニスト
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
JP5081161B2 (ja) 2005-12-19 2012-11-21 スミスクライン ビーチャム コーポレーション ファルネソイドx受容体アゴニスト
CA2640476A1 (en) 2006-02-03 2007-08-16 Eli Lilly And Company Compounds and methods for modulating fx-receptors
BRPI0712262A2 (pt) 2006-05-24 2012-07-10 Lilly Co Eli agonistas de fxr
US8106077B2 (en) 2006-05-24 2012-01-31 Eli Lilly And Company Compounds and methods for modulating FXR
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
WO2008094556A2 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
WO2008157270A1 (en) 2007-06-13 2008-12-24 Smithkline Beecham Corporation Farnesoid x receptor agonists
CA2690406A1 (en) 2007-07-02 2009-01-08 Glaxosmithkline Llc Farnesoid x receptor agonists
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
AU2008317057B8 (en) 2007-10-22 2014-02-13 Merck Sharp & Dohme Corp. Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
US20110230493A1 (en) 2008-11-21 2011-09-22 Pfizer Inc. 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors
JP2012532914A (ja) 2009-07-15 2012-12-20 メルク セローノ ソシエテ アノニム テトラゾール誘導体
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2012087520A1 (en) 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
JP2014500319A (ja) 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー ファルネソイドx受容体を調節するための組成物および方法
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
JP6099753B2 (ja) 2012-10-03 2017-03-22 アドビナス セラピューティクス リミテッド スピロ環化合物、その組成物及びその医薬応用
WO2015172747A1 (en) 2014-05-16 2015-11-19 Zhaoyin Wang Spirocyclic molecules as mth1 inhibitors
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
US20170368038A1 (en) 2014-12-18 2017-12-28 Novartis Ag Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
CN106146483A (zh) 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
WO2017049173A1 (en) 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CN106946867B (zh) 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
WO2017133521A1 (zh) 2016-02-01 2017-08-10 山东轩竹医药科技有限公司 Fxr受体激动剂
CN107021958A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
MX384205B (es) 2016-02-22 2025-03-14 Novartis Ag Metodos para usar agonistas de fxr.
SI3419624T1 (sl) 2016-02-22 2021-05-31 Novartis Ag Postopki za uporabo agonistov FXR
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
CN108430998B (zh) 2016-09-28 2021-07-09 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
CN106632294A (zh) 2016-12-15 2017-05-10 宁波百纳西药业有限公司 一种螺环化合物及其药物用途
IL269068B (en) 2017-03-15 2022-09-01 Metacrine Inc Paranoid x receptor agonists and uses thereof
LT3609888T (lt) 2017-03-15 2025-11-10 Farnezoidinio x receptoriaus agonistai ir jų panaudojimas
WO2018170167A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170173A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170165A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof

Similar Documents

Publication Publication Date Title
JP2021501218A5 (https=)
JP2021501805A5 (https=)
ES3013256T3 (en) Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
JP2021501806A5 (https=)
JP2021501220A5 (https=)
HRP20200962T1 (hr) Novi spojevi
RU2015129538A (ru) Замещенные имидазопиридины в качестве ингибиторов hdm2
TWI494314B (zh) 5,7-取代的-咪唑并[1,2-c]嘧啶
ES2794654T3 (es) Derivados de 4-amino-2-(1H-pirazolo[3,4-b]piridin-3-il)-6-oxo-6,7-dihidro-5H-pirrolo[2,3-d]pirimidina y los respectivos derivados de (1H-indazol-3-il) como moduladores de GMPc para el tratamiento de enfermedades cardiovasculares
JP5775070B2 (ja) ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体
CN105339370B (zh) 用于治疗炎症性疾病的化合物和及其药物组合物
JP2017530960A5 (https=)
JP2020514267A5 (https=)
JP2020527560A5 (https=)
US11254668B2 (en) Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives
WO2018218133A1 (en) Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
JP2016507551A5 (https=)
JP2019535728A (ja) キナーゼ阻害剤としての複素環式アミド
JP2015521634A5 (https=)
JP2016500073A5 (https=)
KR20220079919A (ko) 헤테로시클릭 rip1 억제 화합물
HRP20160539T1 (hr) Antagonisti trpv4
JP2021501219A5 (https=)
JP2017518326A5 (https=)
JP2018505903A5 (https=)